Latest glioblastoma Stories
In response to an article published by U.S.
Results from a clinical trial of a new treatment for glioblastoma suggest that researchers may have found a new approach to treating this most aggressive of brain tumors, as well as a potential new biological marker than can predict the tumor's response to treatment.
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer.
Columbia researchers find that about 15 percent of glioblastoma patients could receive personalized treatment with drugs currently used in other cancers
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting.
A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin®).
- A woman chauffeur.
- A woman who operates an automobile.